Metcela
メトセラ
Business focus
MedTech, BioTech & Pharma
Description
Metcela Inc. is a Kawasaki (Kanagawa), Japan-based clinical-stage regenerative-medicine startup founded in 2016 by Dr. Takahiro Iwamiya and Kenichi Nogami, commercializing Iwamiya's doctoral research on VCAM-1-positive cardiac fibroblasts at Tokyo Women's Medical University. Its lead program, MTC001, is an autologous cardiac-fibroblast cell therapy in Phase 1 trials for ischemic heart failure; it acquired Japan Regenerative Medicine Co. in 2022 (adding pediatric congenital heart disease program JRM-001) and completed a $14 million Series C the same year.